NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Webinar: Quantitative Modeling in Support of the Development of a Lupus Drug

From: Rebecca Baillie <>
Date: Tue, 5 Dec 2017 15:47:50 +0000

Quantitative Modeling in Support of the Development of a Systemic Lupus Erythematosus Drug

Konstantinos (Kostas) Biliouris, PhD
Principal Pharmacometrics Scientist, Novartis, Cambridge, MA, USA

Wednesday, Dec 13, 2017, 12:00 pm to 1:00 pm EST

Register at

Abstract: Systemic lupus erythematosus (SLE) is a rare, chronic auto-immune disease. Type I interferons, that are primarily produced in plasmacytoid dentritic cells, play a major role in the pathogenesis of SLE as well as its cutaneous form CLE.

BIIB059 is a humanized Fc effector function-competent immunoglobulin G1 monoclonal antibody (mAb) under development for the treatment of SLE and CLE. It specifically binds BDCA2, a receptor uniquely expressed on the surface of human and non-primate pDCs. BDCA2 receptor engagement by BIIB059 has been shown to mediate inhibition of IFNα/β expression, which is expected not only to treat the active disease (e.g. lupus skin lesions) but also to inhibit disease progression in SLE.

In this presentation, I will be discussing the development of a population PK/PD model for BIIB059. This model will be utilized in selecting the doses for upcoming Phase 2 studies.
Received on Tue Dec 05 2017 - 10:47:50 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: